Kuo P C, Schroeder R A, Vagelos R H, Valantine H, Garcia G, Alfrey E J, Haddow G, Dafoe D C
Department of Surgery, Stanford University Medical Center, USA.
Clin Transplant. 1996 Dec;10(6 Pt 1):521-7.
Pulmonary hypertension, defined as mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg, is a recognized complication of hepatic dysfunction with portal hypertension and is considered a relative contraindication to liver transplantation. To characterize pulmonary hemodynamic responses in OLT candidates without pre-existing primary pulmonary hypertension, 22 consecutive patients referred for OLT at the Stanford University Hospital underwent prospective right heart catheterization with pressure determinations at baseline and following infusion of 11 crystalloid over 10 min. In addition, EKG, chest X-ray and transthoracic echocardiograms were performed as a part of the routine evaluation. Eleven non-cirrhotic patients served as controls. At baseline, 1/22 (4.5%) OLT patients had pulmonary hypertension while 9/22 (41%) developed pulmonary hypertension following volume infusion (p < 0.0001). In contrast, 0/11 controls manifested elevated pulmonary pressures at baseline or following volume challenge. OLT candidates were found to have significant increases in mean pulmonary pressure and capillary wedge pressure (PCWP) compared to controls, suggesting intravascular volume overload or left ventricular dysfunction as potential causes. OLT candidates who manifested volume-dependent pulmonary hypertension (a) had a 2-fold higher baseline PCWP, (b) currently smoked, and (c) had previously undergone portosystemic shunts. Aggregate analysis of EKG, echo and CXR for determination of volume-mediated pulmonary hypertension revealed a sensitivity of 25%, specificity of 75% and a positive predictive value of 40%. Preoperative identification of patients with a predisposition to manifesting elevated pulmonary pressures in the context of rapid volume infusion offers the potential for improved risk stratification and optimized clinical management.
肺动脉高压定义为平均肺动脉压(mPAP)大于或等于25 mmHg,是肝功能不全合并门静脉高压的一种公认并发症,被视为肝移植的相对禁忌证。为了描述无原发性肺动脉高压病史的肝移植候选者的肺血流动力学反应,斯坦福大学医院连续22例接受肝移植的患者接受了前瞻性右心导管检查,在基线时及静脉输注晶体液11分钟后测定压力。此外,作为常规评估的一部分,还进行了心电图、胸部X线和经胸超声心动图检查。11例非肝硬化患者作为对照。基线时,22例肝移植患者中有1例(4.5%)患有肺动脉高压,而9例(41%)在液体输注后出现肺动脉高压(p<0.0001)。相比之下,11例对照者在基线时或液体负荷后均未出现肺动脉压升高。与对照组相比,肝移植候选者的平均肺动脉压和肺毛细血管楔压(PCWP)显著升高,提示血管内容量超负荷或左心室功能障碍可能是原因。表现为容量依赖性肺动脉高压的肝移植候选者:(a)基线PCWP高2倍,(b)目前吸烟,(c)既往接受过门体分流术。通过心电图、超声心动图和胸部X线的综合分析来确定容量介导的肺动脉高压,其敏感性为25%,特异性为75%,阳性预测值为40%。术前识别在快速容量输注时易出现肺动脉压升高的患者,有可能改善风险分层并优化临床管理。